Maas BiolAB, LLC SBIR Enters Phase 2 for Cyclosporin ALS Treatment

Published: Dec 03, 2008

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Maas Biolab has advanced to Phase 2 of its Small Business Innovation Research (SBIR) grant “Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis (ALS).” Jenny Karlsson, Ph.D., is Maas Director of Preclinical Development and Principal Investigator of the $2.1 million three-year grant from the National Institute of Neurological Disorders and Stroke (NINDS). After successful completion of Phase 1 established initial Mitogard® stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was released by the National Institutes of Health (NIH).

Back to news